Genkyotex Exceeds Patient Enrollment Target in its Phase 2 Trial with GKT831 for Primary Biliary Cholangitis

Genkyotex Exceeds Patient Enrollment Target in its Phase 2 Trial with GKT831 for Primary Biliary Cholangitis

Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces today the completion of enrollment in its Phase 2 trial of GKT831 in patients with Primary Biliary Cholangitis (PBC). The study enrolled a total of 111 patients in nine countries, exceeding the initial target of 102 subjects.

More information on

https://www.genkyotex.com/images/PDF/GB/1_Press_Releases/2018/Genkyotex_PR_Full_enrollment_26092018.pdf